European Commission Approves Shire’s Gaucher Drug

MBBP client Shire Human Genetic Therapies was recently featured in a Boston Business Journal article. Shire's Gaucher disease treatment VPRIV  was approved by the European Commission, thereby allowing VPRIV to be marketed in thirty European countries. VPRIV approval by the U.S. Food and Drug Administration in March 2010 was fast-tracked due to the shortage of Genzyme Corporation's Gaucher drug Cerezyme. For more …

Continue reading European Commission Approves Shire’s Gaucher Drug

Patient Data Shows Safe Switch from Genzyme to Shire Drug

Due to the temporary closing of Genzyme's Allston plant last summer, MBBP client Shire's new Gaucher Disease treatment VPRIV was fast-tracked and approved by the FDA. Shire is now reporting data from a Phase 3 study which showed that when patients switched from Genzyme's Cerezyme to Shire's VPRIV, in the same dosage, several key health …

Continue reading Patient Data Shows Safe Switch from Genzyme to Shire Drug

FDA Approves Shire’s New Gaucher Drug

MBBP client Shire Human Genetic Therapies, a global specialty biopharmaceutical company, announced last week that the U.S. Food and Drug Administration has approved their new drug VPRIV. VPRIV is a human cell line derived enzyme replacement therapy (ERT) meant to help treat Type 1 Gaucher disease. Shire’s drug has been prescribed to patients before its approval on an …

Continue reading FDA Approves Shire’s New Gaucher Drug